主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PLX
#3115
Protalix BioTherapeutics, Inc. Common Stock
2.830
0
USD
+1.07%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
+1.07%
每月变动
-3.08%
6个月变化
-3.08%
年变化
-3.08%
前一天收盘价
2.800
0
Open
2.820
0
Bid
2.830
0
Ask
2.833
0
Low
2.789
0
High
2.845
0
交易量
288
市场
股票
医疗保健
PLX
Open full chart
Financials
Overview
声明
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
73.63 M
78.03 M
79.61 M
79.73 M
80.42 M
—
Valuation ratios
Enterprise value
47.7 M
126.94 M
184.34 M
100.11 M
164.89 M
576.27 M
Price to earnings ratio
-8.5
47
51.2
16.44
27.75
142.39
Price to sales ratio
1.68
2.85
3.26
1.84
2.82
10.78
Price to cash flow ratio
50.02
17.57
21
6.2
9.64
54.4
Price to book ratio
0.62
3.53
1.31
0.67
0.91
6.41
Enterprise value to EBITDA ratio
-6.31
-36.71
56.42
14.49
32.39
66.6
Profitability ratios
Return on assets %
-0.05
-0.01
0.05
-0
-0.03
0.01
Return on equity %
-0.1
-0.01
0.08
-0
-0.04
0.02
Return on invested capital %
-62.76
1.73
39.94
-15.1
-15.89
10.67
Gross margin %
53.37
78.67
19.11
62.51
53.37
213.66
Operating margin %
-22.22
3.43
40.99
-7.48
-11.94
24.99
EBITDA margin %
24.05
41.4
-64.16
9.78
14.02
1.05
Net margin %
-18.02
-3.46
35.79
-1.05
-13.19
18.09
Liquidity ratios
Quick ratio
1.27
1.52
1.69
1.84
2.06
7.1
Current ratio
1.98
2.34
2.49
2.72
3.03
10.58
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.23
0.27
0.14
0.21
0.22
0.83
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0
—
—
—
—
Long term debt to total equity ratio
—
0
—
—
—
—
Per share metrics
Operating cash flow per share
0.06
0.05
0.07
0.07
0.05
0.23
EBIT per share
0.05
0.09
-0.09
0.02
0.03
0.04
EBITDA per share
0.06
0.09
-0.08
0.02
0.03
0.06
Total debt per share
—
—
—
—
—
—
Cash per share
0.37
0.24
0.25
0.23
0.17
0.9
Net current asset value per share
0.65
0.74
0.79
0.84
0.85
3.22
Tangible book value per share
0.44
0.53
0.59
0.64
0.68
2.44
Working capital per share
0.32
0.43
0.47
0.53
0.57
2
Book value per share
0.44
0.53
0.59
0.64
0.68
2.44
Protalix BioTherapeutics Inc (DE)
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
新闻
Brazil judge overrules decisions suspending changes to meal voucher system
A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)
Pluxee, Edenred shares jump after upbeat results and outlook
Pluxee 2026财年第一季度报告:在巴西挑战中实现9%收入增长
Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds
Protalix公司概述2026年战略,聚焦难治性痛风疗法
Tuesday’s Insider Activity: Key Execs Make Notable Trades
Protalix BioTherapeutics首席执行官Bashan Dror购入价值10.1万美元股票
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)
Protalix与Secarna合作开发罕见肾脏疾病治疗方案
Protalix and Secarna partner to develop rare kidney disease treatments
Pluxee因巴西监管变化修订2026财年展望